MARIANA CHAVEZ MAC GREGOR
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 45 | 2022 | 15694 | 2.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2015 | 3251 | 0.930 |
Why?
|
| Receptor, ErbB-2 | 13 | 2019 | 2518 | 0.780 |
Why?
|
| Breast Neoplasms, Male | 3 | 2015 | 229 | 0.770 |
Why?
|
| Bridged-Ring Compounds | 2 | 2011 | 183 | 0.740 |
Why?
|
| Anthracyclines | 2 | 2011 | 331 | 0.670 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2015 | 3890 | 0.630 |
Why?
|
| Taxoids | 3 | 2012 | 967 | 0.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2019 | 15862 | 0.600 |
Why?
|
| Menstrual Cycle | 2 | 2007 | 56 | 0.550 |
Why?
|
| Population Surveillance | 2 | 2013 | 627 | 0.540 |
Why?
|
| Neoadjuvant Therapy | 10 | 2015 | 4975 | 0.530 |
Why?
|
| Trastuzumab | 5 | 2015 | 696 | 0.480 |
Why?
|
| Antineoplastic Agents | 9 | 2015 | 14289 | 0.470 |
Why?
|
| Acromegaly | 1 | 2013 | 27 | 0.460 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 1216 | 0.450 |
Why?
|
| Octreotide | 1 | 2013 | 118 | 0.440 |
Why?
|
| Diphosphonates | 2 | 2011 | 262 | 0.420 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 292 | 0.400 |
Why?
|
| Receptors, Estrogen | 10 | 2019 | 2086 | 0.390 |
Why?
|
| Neoplasm Staging | 15 | 2017 | 13658 | 0.370 |
Why?
|
| Proportional Hazards Models | 10 | 2017 | 4988 | 0.370 |
Why?
|
| Thromboembolism | 1 | 2011 | 155 | 0.360 |
Why?
|
| Erythropoietin | 1 | 2011 | 205 | 0.350 |
Why?
|
| SEER Program | 4 | 2015 | 1000 | 0.340 |
Why?
|
| Receptors, Progesterone | 9 | 2019 | 1392 | 0.340 |
Why?
|
| Female | 48 | 2024 | 141928 | 0.340 |
Why?
|
| Heart Diseases | 1 | 2015 | 732 | 0.330 |
Why?
|
| Mastectomy, Segmental | 4 | 2014 | 1026 | 0.320 |
Why?
|
| Postmenopause | 4 | 2019 | 378 | 0.320 |
Why?
|
| Mastectomy | 2 | 2013 | 1534 | 0.320 |
Why?
|
| Sirolimus | 1 | 2012 | 814 | 0.320 |
Why?
|
| Aged | 28 | 2022 | 70117 | 0.300 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2007 | 110 | 0.290 |
Why?
|
| Neoplasms, Second Primary | 3 | 2024 | 1350 | 0.290 |
Why?
|
| Disease-Free Survival | 10 | 2017 | 10001 | 0.280 |
Why?
|
| Prognosis | 13 | 2019 | 21713 | 0.280 |
Why?
|
| Risk Factors | 10 | 2017 | 17523 | 0.270 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 1011 | 0.260 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2015 | 6207 | 0.260 |
Why?
|
| Humans | 51 | 2024 | 261506 | 0.250 |
Why?
|
| Hypertension | 2 | 2013 | 1503 | 0.250 |
Why?
|
| Radiation Oncology | 3 | 2014 | 529 | 0.250 |
Why?
|
| Neoplasm Metastasis | 5 | 2017 | 5112 | 0.240 |
Why?
|
| Thrombosis | 1 | 2011 | 781 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 4 | 2022 | 2403 | 0.230 |
Why?
|
| Sternum | 1 | 2013 | 100 | 0.230 |
Why?
|
| Aged, 80 and over | 12 | 2021 | 29902 | 0.220 |
Why?
|
| Skin Diseases | 1 | 2005 | 349 | 0.220 |
Why?
|
| Middle Aged | 27 | 2022 | 86204 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2330 | 0.210 |
Why?
|
| Stroke | 1 | 2011 | 1144 | 0.210 |
Why?
|
| Thoracic Wall | 1 | 2013 | 183 | 0.200 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2022 | 1415 | 0.200 |
Why?
|
| Aromatase Inhibitors | 1 | 2013 | 305 | 0.190 |
Why?
|
| Lymphatic Metastasis | 6 | 2014 | 4844 | 0.190 |
Why?
|
| Thoracic Neoplasms | 1 | 2013 | 337 | 0.190 |
Why?
|
| Wound Healing | 1 | 2005 | 815 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2015 | 419 | 0.180 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2014 | 1215 | 0.180 |
Why?
|
| Heart Failure | 1 | 2013 | 2516 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 4757 | 0.170 |
Why?
|
| United States | 7 | 2022 | 15433 | 0.170 |
Why?
|
| Tamoxifen | 1 | 2013 | 876 | 0.170 |
Why?
|
| Triazoles | 1 | 2013 | 617 | 0.170 |
Why?
|
| Age Factors | 6 | 2015 | 5377 | 0.160 |
Why?
|
| Nitriles | 1 | 2013 | 906 | 0.160 |
Why?
|
| Axilla | 1 | 2021 | 902 | 0.160 |
Why?
|
| Neoplasm, Residual | 3 | 2014 | 1656 | 0.160 |
Why?
|
| Adult | 21 | 2024 | 77950 | 0.160 |
Why?
|
| Treatment Outcome | 9 | 2015 | 32848 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 840 | 0.160 |
Why?
|
| Comorbidity | 2 | 2015 | 2352 | 0.160 |
Why?
|
| Premature Birth | 1 | 2022 | 407 | 0.150 |
Why?
|
| Biomarkers, Tumor | 7 | 2015 | 10331 | 0.150 |
Why?
|
| Epirubicin | 2 | 2015 | 157 | 0.150 |
Why?
|
| Medicare | 2 | 2013 | 860 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2015 | 10035 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2022 | 9244 | 0.140 |
Why?
|
| Retrospective Studies | 10 | 2022 | 37905 | 0.140 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2022 | 509 | 0.140 |
Why?
|
| Menarche | 2 | 2007 | 50 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2012 | 1678 | 0.130 |
Why?
|
| Survival Rate | 5 | 2019 | 12221 | 0.130 |
Why?
|
| Heart Function Tests | 1 | 2015 | 73 | 0.130 |
Why?
|
| Overweight | 1 | 2019 | 484 | 0.130 |
Why?
|
| Everolimus | 2 | 2019 | 415 | 0.130 |
Why?
|
| Metformin | 1 | 2019 | 378 | 0.130 |
Why?
|
| Texas | 3 | 2015 | 6311 | 0.130 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 1323 | 0.120 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2015 | 145 | 0.120 |
Why?
|
| Time Factors | 4 | 2015 | 12926 | 0.120 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 1742 | 0.120 |
Why?
|
| Health Plan Implementation | 1 | 2014 | 90 | 0.120 |
Why?
|
| Carcinoma, Lobular | 2 | 2014 | 611 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 6009 | 0.120 |
Why?
|
| Societies, Medical | 3 | 2014 | 1335 | 0.110 |
Why?
|
| Fluorouracil | 2 | 2015 | 1944 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2015 | 333 | 0.110 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 223 | 0.110 |
Why?
|
| California | 1 | 2013 | 208 | 0.110 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 4298 | 0.100 |
Why?
|
| Genes, erbB-2 | 1 | 2013 | 229 | 0.100 |
Why?
|
| Remission Induction | 2 | 2015 | 3569 | 0.100 |
Why?
|
| Receptors, Steroid | 1 | 2012 | 286 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2013 | 1053 | 0.100 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2011 | 84 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2015 | 1996 | 0.090 |
Why?
|
| Cyclophosphamide | 2 | 2015 | 3001 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2005 | 5542 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 573 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 622 | 0.090 |
Why?
|
| Consensus | 1 | 2014 | 978 | 0.090 |
Why?
|
| Lymph Node Excision | 2 | 2014 | 1959 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 2283 | 0.090 |
Why?
|
| Patient Selection | 2 | 2015 | 2055 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 4 | 2015 | 3981 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 8865 | 0.090 |
Why?
|
| Young Adult | 4 | 2015 | 21445 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 323 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2011 | 241 | 0.080 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2007 | 40 | 0.080 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 384 | 0.070 |
Why?
|
| Parity | 1 | 2007 | 139 | 0.070 |
Why?
|
| Menopause | 1 | 2007 | 159 | 0.070 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 973 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2014 | 1824 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 2291 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2884 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2576 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 4314 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 1546 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2014 | 2231 | 0.070 |
Why?
|
| Gene Expression | 1 | 2013 | 3570 | 0.070 |
Why?
|
| Proteomics | 1 | 2012 | 1380 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2010 | 607 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2014 | 1423 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2054 | 0.060 |
Why?
|
| Mexico | 1 | 2005 | 259 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 5539 | 0.060 |
Why?
|
| Imidazoles | 1 | 2010 | 999 | 0.060 |
Why?
|
| Necrosis | 1 | 2005 | 580 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 543 | 0.060 |
Why?
|
| Europe | 1 | 2005 | 649 | 0.060 |
Why?
|
| Prevalence | 1 | 2011 | 3260 | 0.060 |
Why?
|
| Premenopause | 1 | 2013 | 131 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 4549 | 0.060 |
Why?
|
| Spouses | 1 | 2024 | 134 | 0.050 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2022 | 59 | 0.050 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2003 | 82 | 0.050 |
Why?
|
| Pregnancy | 2 | 2022 | 7573 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 14889 | 0.050 |
Why?
|
| Bone Marrow | 2 | 2010 | 2358 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 98 | 0.050 |
Why?
|
| Male | 6 | 2024 | 123000 | 0.050 |
Why?
|
| Fetal Growth Retardation | 1 | 2022 | 194 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2015 | 1163 | 0.050 |
Why?
|
| Canada | 1 | 2021 | 429 | 0.050 |
Why?
|
| Parenting | 1 | 2024 | 345 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2022 | 367 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2024 | 764 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 383 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2005 | 927 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 1547 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 4849 | 0.040 |
Why?
|
| Androstadienes | 1 | 2019 | 165 | 0.040 |
Why?
|
| Caregivers | 1 | 2024 | 677 | 0.040 |
Why?
|
| Neoplasms | 1 | 2024 | 15193 | 0.040 |
Why?
|
| Parents | 1 | 2024 | 998 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2013 | 9180 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 4367 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2019 | 12873 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2005 | 6100 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 175 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 586 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 227 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 2315 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 3719 | 0.030 |
Why?
|
| Ultrasonography, Mammary | 1 | 2014 | 380 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2012 | 303 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2015 | 1869 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 487 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 521 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 501 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 2944 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8223 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 829 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2011 | 305 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1987 | 0.020 |
Why?
|
| Mammography | 1 | 2014 | 1010 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2015 | 7226 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 2218 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 7548 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 1209 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 2466 | 0.020 |
Why?
|
| Infant | 1 | 2022 | 13310 | 0.020 |
Why?
|
| Surgeons | 1 | 2014 | 519 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 1303 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 4892 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2022 | 16273 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2012 | 3005 | 0.020 |
Why?
|
| Microcirculation | 1 | 2005 | 200 | 0.020 |
Why?
|
| Breast | 1 | 2011 | 1344 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 593 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2012 | 4804 | 0.010 |
Why?
|
| Registries | 1 | 2011 | 2170 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 6295 | 0.010 |
Why?
|
| Nervous System Neoplasms | 1 | 2003 | 36 | 0.010 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2003 | 42 | 0.010 |
Why?
|
| Recurrence | 1 | 2011 | 4758 | 0.010 |
Why?
|
| Child | 1 | 2024 | 29154 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 6869 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 1054 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2005 | 943 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2011 | 2967 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 11538 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 2316 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 14551 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 8873 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 15179 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2005 | 4078 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2003 | 1870 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 59536 | 0.010 |
Why?
|